Piramal Imaging Adds New AD Tracers For Leadership In Neuroimaging Research
This article was originally published in PharmAsia News
Piramal is working on what it claims is a well-rounded strategy for an international edge in the field of neuroimaging research. While it is adding newer tracers for detection of the root causes of Alzheimer’s disease, its first approved product Neuraceq is ready to hit the U.S. and European markets later this year.
You may also be interested in...
Selecting the right patients for clinical trials of potential Alzheimer’s disease therapies could be easier if an agreement on the development of a PET-based diagnostic between the companies bears fruit.
Neuraceq will be the third entrant into the beta-amyloid imaging market, a space already limited by concerns about the clinical utility of PET scans in Alzheimer’s disease management.
Clinical trial results reported at AAIC demonstrate the variety of approaches, from novel to repurposed, in play as drugmakers attempt to delay the onset, slow the progression or even prevent the world’s second-most dreaded disease. It’s an arena in which first-in-human data can achieve rock star status.